Key Highlights
- Morgan Stanley maintains Overweight rating on Eli Lilly (LLY) with price target of $1,313
- Mounjaro prescriptions reached approximately 724,500 weekly, climbing from around 705,300
- Zepbound scripts surged to roughly 598,100, rising from approximately 500,900 previously
- Lilly commands about 60% of the weekly new prescription share in the GLP-1 market
- Fourth-quarter EPS of $7.54 exceeded expectations, with revenues climbing 42.6% annually
Prescription volumes for Eli Lilly’s leading weight management and diabetes medications, Mounjaro and Zepbound, demonstrated continued expansion during the week concluded February 27, 2026, based on IQVIA analytics referenced by Morgan Stanley.
Mounjaro’s total prescription count climbed to approximately 724,500 for the reported week, representing an increase from the previous week’s figure of around 705,300. Fresh prescriptions for Mounjaro totaled roughly 361,600, advancing from 352,700 recorded earlier.
Zepbound demonstrated more pronounced momentum. Overall prescriptions reached about 598,100, escalating from 500,900 during the preceding week. Fresh prescriptions climbed to 328,300 from 298,600.
Morgan Stanley maintained its Overweight stance on LLY while preserving its $1,313 price objective. The investment bank anticipates approximately 7% potential upside to its 2026 projections for both medications collectively.
Aggregated GLP-1 prescription activity for Lilly and Novo Nordisk expanded by roughly 30% on a year-over-year basis, underscoring sustained robust demand throughout the therapeutic category.
Lilly’s comprehensive GLP-1 portfolio — encompassing Mounjaro, Zepbound, and Trulicity — captured approximately 60% of the weekly new prescription market share, edging higher from the prior week’s 59% figure.
Financial Performance and Results
LLY delivered Q4 EPS of $7.54, surpassing the analyst consensus estimate of $7.48 by $0.06. Quarterly revenue totaled $19.29 billion, significantly exceeding the projected $17.85 billion. This represented a 42.6% year-over-year increase from the comparable period.
The pharmaceutical giant established its FY2026 EPS guidance range at $33.50–$35.00. Quarterly net margin registered at 31.66%, while return on equity measured 102.94%.
Lilly increased its quarterly dividend payment to $1.73, advancing from $1.50. The annualized distribution now totals $6.92, delivering a yield of approximately 0.7%.
Shares commenced Friday trading at $982.85. The 52-week trading range extends from $623.78 to $1,133.95. The 50-day moving average registers at $1,047.37, while the 200-day average stands at $937.23.
Wall Street Coverage and Institutional Holdings
Institutional investors currently control 82.53% of LLY shares. Several firms expanded their positions throughout Q3 2026, including KCM Investment Advisors, which increased its holdings by 14%, and M1 Capital Management, which boosted its stake by 10.8%.
Integrity Advisory Solutions established a fresh position valued at approximately $1.07 million during the reporting period.
The aggregate analyst sentiment registers as “Moderate Buy” with a mean price objective of $1,229.59. Wells Fargo elevated its target to $1,280 accompanied by an Overweight rating. Jefferies increased its target to $1,300, assigning the stock a Buy rating. Royal Bank of Canada initiated coverage with an Outperform designation and a $1,250 price objective.
Seven Wall Street analysts revised their earnings projections upward following the fourth-quarter earnings release.
Lilly additionally introduced its “Employer Connect” initiative, structured to facilitate employer-sponsored coverage for obesity treatments, including Zepbound, featuring a $449 single-patient KwikPen pricing alternative.
Orforglipron, Lilly’s investigational oral GLP-1 therapy, demonstrated superiority over oral semaglutide in a Type 2 diabetes clinical trial across both primary and secondary endpoints.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
